Re-irradiation using boron neutron capture therapy for recurrent oral squamous cell carcinoma: the impact of tumor volume and early response on survival.

Authors

Kanako Takayama, Ichiro Seto, Takashi Ono, Yoshiaki Takagawa, Shinya Komori, Ryohei Kato, Akihiko Takeuchi, Yuhei Yamazaki, Tomoaki Motoyanagi, Yuki Narita, Shunsuke Komatsu, Takahiro Kato, Yoshihiro Takai

Published in

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]. Sep 22, 2026. Epub Sep 22, 2026.

Abstract

Re-irradiation for recurrent oral cancer remains clinically challenging due to limited treatment efficacy and severe toxicity. In this study, we evaluated the clinical outcomes of boron neutron capture therapy (BNCT) and explored prognostic factors associated with survival in oral squamous cell carcinoma (OSCC).
We conducted a retrospective single-institution cohort study of 45 patients with recurrent OSCC treated with accelerator-based BNCT between June 2020 and December 2022. Overall survival (OS), local control (LC), and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Prognostic factors were assessed using Cox proportional hazards models.
The objective response rate was 80%. At a median follow-up of 25 months, the 2‑year OS, LC, and PFS rates were 51.1%, 31.8%, and 22.2%, respectively. In the univariate analysis, tumor volume was associated with OS (p = 0.036). Exploratory analyses suggested that tumor volumes ≥ 20 cm³ may be associated with inferior OS, and ≥ 25 cm³ with inferior OS and LC (p < 0.05). Patients achieving complete response (CR) within 90 days had better OS than those without CR (HR, 3.73; 95% CI, 1.50-9.30; p = 0.005). Grade ≥ 3 acute mucositis occurred in 49% of patients, and late grade ≥ 3 osteoradionecrosis occurred in 10%.
BNCT may be an option for selected patients with recurrent OSCC after prior irradiation. Favorable responses and OS were observed, although LC remained limited and toxicities required careful management. Baseline tumor volume warrants further study for survival risk stratification, while early response may aid prognostic assessment.

PMID:
42773313
Bibliographic data and abstract were imported from PubMed on 23 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.